356-P: Population Pharmacokinetic Modeling of Dasiglucagon in Subjects with Type 1 Diabetes Mellitus

Knudsen, Carsten; Valeur, Anders; Maarbjerg, Stine; Tehranchi, Ramin; Diderichsen, Paul; Witjes, Han

doi:10.2337/db21-356-p

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…for reconstituted glucagon 1.0 mg [18]. Model-predicted effects of covariates (kidney function, bodyweight, injection site and age) on dasiglucagon area under the plasma concentration-time curve (AUC) generally fell within the observed AUC for the overall analysis population [20].…”

Section: Chemistry and Mechanism Of Actionmentioning

confidence: 80%

“…Based on population pharmacokinetic modeling, dasiglucagon pharmacokinetics can be described by a onecompartment model, with first-order absorption and elimination, including an absorption lag time and standard allometric relations to bodyweight [20]. Following SC injection, dasiglucagon plasma concentrations rapidly increased in a dose-proportional manner [18], with a t max [time to maximum plasma concentration (C max )] of ≈ 35 min [14,18].…”

Section: Pharmacokinetic Profilementioning

confidence: 99%

See 1 more Smart Citation

Dasiglucagon in severe hypoglycemia: a profile of its use

Syed

2022

Drugs Ther Perspect

View full text Add to dashboard Cite

Subcutaneous dasiglucagon (Zegalogue ® ), a next generation glucagon analog, is a convenient and valuable addition to readyto-use glucagon formulations for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes. A single dose of dasiglucagon reverses insulin-induced hypoglycemia typically within 10 min in this population, without need for additional intervention. The drug is generally well tolerated, with nausea and vomiting being the most frequent adverse reactions. The overall safety profile of dasiglucagon is consistent with that expected for glucagon treatment. Dasiglucagon is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature. Plain Language SummaryGlucagon emergency kits are a standard treatment option for hypoglycemia, a potential serious complication of diabetes treatment. They require mixing of glucagon powder in sterile water before administration; this step may cause errors and delay in an emergency situation. Thus, ready-to-use glucagon formulations have been developed. Subcutaneous dasiglucagon (Zegalogue ® ), a ready-to-use next generation glucagon analog, is approved in the USA for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes. Dasiglucagon reverses hypoglycemia typically within 10 min, without need for additional intervention, and is well tolerated. The drug is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature. Thus, dasiglucagon is a convenient and valuable addition to ready-to-use glucagon formulations for the treatment of severe hypoglycemia.

show abstract

Section: Chemistry and Mechanism Of Actionmentioning

confidence: 80%